Lung Cancer
Conditions
Brief summary
The purpose of this study is studying induction nimotuzumab plus gemcitabine and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III squamous cell lung carcinoma.
Detailed description
Concurrent chemoradiotherapy is the recommended therapeutic approach for patients with unresectable stage III non-small cell lung cancer (NSCLC), although surgery offers the chance of cure. With combined-modality therapy with radiation therapy and chemotherapy, the prognosis of stage III NSCLC remains poor. Nimotuzumab, a human anti-EGFR monoclonal antibody, has shown its efficacy in the treatment of head/neck squamous cell carcinoma, nasopharyngeal carcinoma as well as lung cancer. This study is studying neoadjuvant nimotuzumab plus gemcitabine and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III squamous cell lung carcinoma.
Interventions
DRUGNimotuzumab
Nimotuzumab was given 200 mg i.v. injection over 30 min on days 1 and 8
DRUGGemcitabine
Gemcitabine was given 1000 mg/m2 i.v. injection on days1 and 8.
DRUGCarboplatin
carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1.
PROCEDURESurgery
Patients' resectability was assessed by a medical team, including thoracic surgeons, medical oncologists, and radiologists.
Sponsors
Sun Yat-sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Target population is unresectable stage III squamous cell lung carcinoma. * Written informed consent provided. * Male and female patients aged ≥18 years, ≤75 years. * Able to comply with the required protocol and follow-up procedures, and able to receive oral medications. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Life expectancy ≥12 weeks. * Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109/L, and Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or exceed this level). * Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN in subjects without liver metastases; ≤ 5 x ULN in subjects with liver metastases. * Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml/min. * Female subjects should not be pregnant or breast-feeding.
Exclusion criteria
* Known severe hypersensitivity to nimotuzumab or any of the excipients of this product. * Inability to comply with protocol or study procedures. * A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study. * A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease. * Patients with prior exposure to agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab). * Patients with prior chemotherapy or therapy with systemic anti-tumour therapy (e.g. monoclonal antibody therapy). * Patients with prior radiotherapy * History of another malignancy in the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted. * Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease). * Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicated the use of an investigational drug or puts the subject at high risk for treatment-related complications. * Patient who has active serious infection (e.g. pyrexia of or 38.0℃ over).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resectability rate | 3 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with perioperative complications | 1 year | — |
| Event-free survival | 2 years after the last patient is enrolled | Event-free survival was assessed from diagnosis to disease recurrence/metastasis/progression or death as a result of any cause. |
| Overall survival | 2 years after the last patient is enrolled | Overall survival was assessed from diagnosis to death as a result of any cause. |
Countries
China
Outcome results
None listed